To the Editor I recently read with great interest the article written by Navari and colleagues1 assessing the effectiveness of low-dose olanzapine, 5 mg/d, administration for relieving nausea/vomiting associated with advanced cancers. This study showed that patients receiving olanzapine experienced a significant improvement in their symptoms compared with those in the placebo arm. Although this pilot study is impressive, there are some concerns that may compromise the validity of the study.
Taherifard E. The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting. JAMA Oncol. 2020;6(11):1811–1812. doi:10.1001/jamaoncol.2020.3703
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.